AbbVie/J&J Withdrawal Of Imbruvica Indications Clears Space For Competitors
Executive Summary
The BTK inhibitor’s exit from MCL and MZL after lackluster Phase III confirmatory trial results gives AstraZeneca’s Calquence and BeiGene’s Brukinsa a potential shot at claiming the space.